These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30429518)

  • 1. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; McCaffrey L; AlKawaz A; Abidi A; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 May; 32(5):639-649. PubMed ID: 30429518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
    Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
    J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
    Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
    Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; Aleskandarany MA; Alkawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1460-1472. PubMed ID: 31175327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
    Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Khout H; Ellis IO; Green AR; Rakha EA
    Br J Cancer; 2018 Dec; 119(12):1518-1526. PubMed ID: 30410060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
    Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
    Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
    Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
    Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
    BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
    Van Bockstal MR; Wesseling J; Lips EH; Smidt M; Galant C; van Deurzen CHM
    Breast Cancer Res; 2024 Aug; 26(1):125. PubMed ID: 39192322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
    Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
    Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
    Al-Kawaz A; Miligy IM; Toss MS; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
    Breast Cancer Res Treat; 2021 Jul; 188(1):53-63. PubMed ID: 34117958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
    Mardekian SK; Bombonati A; Palazzo JP
    Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.